All
Environmental problems impact derms
March 1st 2005New Orleans — Various environmental phenomena, such as the depletion of tropical rain forests, can affect human health — for instance, by eliminating the potential for lifesaving medications, says Peyton Weary, M.D., professor emeritus of dermatology at the University of Virginia and former president of the National Association of Physicians for the Environment.
Assessing the face for filler use
February 21st 2005Richard G. Glogau, M.D., clinical professor of dermatology, University of California, San Francisco, spoke about the best way to obtain satisfactory outcomes in soft tissue augmentation, yesterday. He said matching defects to appropriate materials and balancing patient expectations and economics along the way are key.
Options in the fight against viruses
February 21st 2005Stephen Tyring, M.D., Ph.D., M.B.A., professor, University of Texas Health Science Center, Houston, presented a talk on the newest advances in antiviral therapy, yesterday. He said, overall, that physicians now have an increase of knowledge pertaining to the diagnosis and management strategies for the herpes virus family, the pox viruses, mumps, measles, rubella, parvovirus B 19 and retroviruses as well as the viral etiologies of hepatitis.
Biologic therapies benefit psoriasis patients, but need more study
February 21st 2005Biologic therapies are promising agents for the treatment of psoriasis, offering successful therapy without the organ toxicity associated with traditional systemic approaches such as methotrexate and cyclosporine, says Jeffrey M. Weinberg, M.D.
DermaQuest glycolic acid cleansers gently exfoliate
February 21st 2005DermaQuest Skin Therapy presents a glycolic acid product line, including two cleansers that contain the acid. The Glycolic Acid Cleanser, a 15 percent glycolic acid formulation, is oil-free and contains encapsulated glycolic acid that exfoliates skin without causing dryness and irritation, the company says.
Novel radiofrequency-based treatment achieves skin tightening with minimal discomfort
February 21st 2005Functional Aspiration Controlled Electrothermal Stimulation (FACES) appears to be a safe, effective, and very well-tolerated technique for reducing the appearance of wrinkles, reported Michael H. Gold, M.D.
Drug combination trumps single-agent acne treatment
February 21st 2005Combining a popular topical retinoid with a widely used antibiotic - and applying them at the same time as if they were one drug - clearly outperforms using either agent separately in treating acne. The key is adding to them a novel aqueous hydrogel which solubilizes the two old stand-by drugs and stabilizes them to provide a particularly effective once-daily treatment.
Surface irregularities post-radiofrequency tissue tightening rare, preventable, treatable
February 20th 2005Subcision with autologous fat transfer is an effective technique for managing patients who have developed surface irregularities after undergoing a radiofrequency tissue tightening procedure, said Rhoda Narins, M.D. at a symposium yesterday.
Lidocaine toxicity a serious risk of laser surgery
February 19th 2005Lidocaine toxicity associated with use of topical anesthetic creams in patients undergoing laser procedures is a major concern that dermatologic surgeons need to be aware of, said Roy G. Geronemus, M.D., speaking in a surgical symposium on "When Bad Things Happen to Good Surgeons."
Methotrexate, TNF inhibitors benefit psoriatic arthritis patients
February 18th 2005Dermatologists should become familiar with both methotrexate and TNF-inhibiting biologic agents to treat the skin and joints because they are often able to diagnose psoriatic arthritis before rheumatologists, Bruce E. Strober, M.D., Ph.D., said yesterday in his presentation on "Psoriatic Arthritis: Diagnosis and Management."
Final results reported from phase 3b study of efalizumab; Data support long-term efficacy and safety
February 18th 2005Results from a 36-month, open label study demonstrate the efficacy and safety of continuous treatment with efalizumab (Raptiva, Genentech) in adults with moderate-to-severe chronic plaque psoriasis, reports Craig L. Leonardi, M.D.